APA (7th ed.) Citation

Antonio Lacquaniti, Patrizio Pasqualetti, Teresa Casuscelli di Tocco, Susanna Campo, Stefania Rovito, Maurizio Bucca, . . . Paolo Monardo. (2020). Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. The Korean Society of Nephrology.

Chicago Style (17th ed.) Citation

Antonio Lacquaniti, Patrizio Pasqualetti, Teresa Casuscelli di Tocco, Susanna Campo, Stefania Rovito, Maurizio Bucca, Antonino Ragusa, and Paolo Monardo. Ferric Carboxymaltose Versus Ferric Gluconate in Hemodialysis Patients: Reduction of Erythropoietin Dose in 4 Years of Follow-up. The Korean Society of Nephrology, 2020.

MLA (9th ed.) Citation

Antonio Lacquaniti, et al. Ferric Carboxymaltose Versus Ferric Gluconate in Hemodialysis Patients: Reduction of Erythropoietin Dose in 4 Years of Follow-up. The Korean Society of Nephrology, 2020.